Lexicon Pharmaceuticals (LX31) Financial Statements
Lexicon Pharmaceuticals Financial Overview
Lexicon Pharmaceuticals's market cap is currently $563.85M. The company's EPS TTM is $-0.15; its P/E ratio is -9.44; Lexicon Pharmaceuticals is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $-0.05. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 49.80M | $ 31.08M | $ 1.20M | $ 139.00K | $ 298.00K |
| Gross Profit | $ 49.53M | $ 30.46M | $ -57.77M | $ -52.38M | $ -54.75M |
| Operating Income | $ -48.91M | $ -197.12M | $ -171.75M | $ -100.76M | $ -87.09M |
| EBITDA | $ -41.38M | $ -184.29M | $ -169.76M | $ -100.03M | $ -86.66M |
| Net Income | $ -50.34M | $ -200.40M | $ -177.12M | $ -101.94M | $ -87.76M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 96.23M | $ 237.96M | $ 170.03M | $ 138.36M | $ 86.74M |
| Total Assets | $ 184.99M | $ 298.42M | $ 229.43M | $ 194.30M | $ 136.91M |
| Total Debt | $ 62.24M | $ 108.40M | $ 106.06M | $ 55.29M | $ 2.28M |
| Net Debt | $ 27.91M | $ 41.74M | $ 83.60M | $ 8.95M | $ -61.79M |
| Total Liabilities | $ 77.45M | $ 152.47M | $ 136.32M | $ 77.17M | $ 23.31M |
| Stockholders' Equity | $ 107.54M | $ 145.95M | $ 93.11M | $ 117.12M | $ 113.59M |
| Cash Flow | |||||
| Free Cash Flow | $ -67.85M | $ -179.81M | $ -162.37M | $ -90.18M | $ -88.24M |
| Operating Cash Flow | $ -67.85M | $ -178.78M | $ -161.90M | $ -88.85M | $ -87.02M |
| Investing Cash Flow | $ 113.02M | $ -15.38M | $ -49.94M | $ -71.08M | $ 2.11M |
| Financing Cash Flow | $ -48.50M | $ 238.35M | $ 187.96M | $ 142.21M | $ 22.71M |
Currency in USD